EGFR和P53在子宫内膜癌中的表达及临床意义

Expression and clinical significance of EGFR and P53 in endometrial carcinoma

目的探讨EGFR和P53在子宫内膜癌中的表达及其临床意义。方法选取2013年1月至2013年10月在我院已确诊为子宫内膜癌的手术切除蜡块标本40例,并取同期不典型增生子宫内膜和正常子宫内膜组织标本各20例,对入组的这80例患者的组织切片均采用免疫组化的方法进行EGFR和P53蛋白测定,将检测结果与相关临床因素进行统计学分析。结果1EGFR及P53在子宫内膜癌组织中的阳性表达明显高于正常增殖期子宫内膜、不典型增生子宫内膜(P<0.05)。2EGFR及P53的表达与子宫内膜癌患者的肌层浸润深度及淋巴结转移有相关性(P<0.05),而与子宫内膜癌患者的病理分期、组织学分级、患者的年龄以及患者是否绝经无相关性(P>0.05)。3EGFR和P53的表达呈正相关(Rs=0.961,P=0.002)。结论 EGFR和P53可能是内膜癌的发病机制之一,其高表达可作为判断子宫内膜癌病情进展的重要指标。联合检测EGFR和P53对子宫内膜癌的诊断及预后预测更具有意义,也为子宫内膜癌的靶向治疗提供一定的参考。

Objective To discuss the expression and significance of EGFR and P53 in endometrial cancer. Methods Collect cases of hysterectomy in our hospital between January 2013 and October 2013,and choose 40 cases of endometrial cancer tissue sections, 20 cases of patients with atypical hyperplasia endometrium tissue section and 20 cases of normal uterine endometrial bi- opsy. Eighty cases of biopsy patients enrolled underwent EGFR and P53 determination by immunohistochemical methods,the test results were analyzed. Results ① EGFR and P53 positive expression in endometrial cancer organizations are significantly higher than the normal period of endometrial proliferation, atypical hyperplasia of endometrium, the comparison between three groups was statistically significant （P〈0.05 ）. ②There were correlations between the expression of EGFR and muscular infil- tration of endometrial carcinoma and lymphatic metastasis, and no correlation with clinical stage, histological grade, age and whether menopause （P〉0.05）.③There was a positive correlation between the expression of EGFR and P53 in endometrial carcinoma statistically（Rs=0. 961,P=0. 002）. Conclusion EGFR and P53 may be one of the pathogenesis of endometrial car- cinoma, and its high expression can be used as a judge of the important indices for endometrial cancer progression. Combined de- tection of EGFR and P53 in diagnosis of endometrial carcinoma and prognosis prediction is more meaningful,and can provide certain reference for endornetrial cancer targeted therapy.